Geographic Atrophy Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Nanoscope Therapeutics, ONL Therapeutics, Roche, NGM Biopharmaceuticals, Annexon, G

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Geographic Atrophy pipeline constitutes 23+ key companies continuously working towards developing 25+ Geographic Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Geographic Atrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Geographic Atrophy Market.

The Geographic Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Geographic Atrophy Pipeline Report: https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Geographic Atrophy treatment therapies with a considerable amount of success over the years.
• Geographic Atrophy companies working in the treatment market are Complement Therapeutics, Aevitas Therapeutics, Nanoscope Therapeutics, ONL Therapeutics, Roche, NGM Biopharmaceuticals, Annexon, Genentech, Apellis Pharmaceuticals, Pegol Iveric Bio, and others, are developing therapies for the Geographic Atrophy treatment
• Emerging Geographic Atrophy therapies in the different phases of clinical trials are- CTx001, AAV.sFH, MCO 020, ONL 1204, RO7303359, NGM621, ANX 007, OpRegen, Pegcetacoplan, Avacincaptad, and others are expected to have a significant impact on the Geographic Atrophy market in the coming years.
• In February 2023, Zimura's NDA for geographic atrophy was accepted by the US FDA, which also gave it priority review with a Prescription Drug User Fee Act (PDUFA) goal date of August 19, 2023.
• In February 2023, SYFOVRE (pegcetacoplan injection), which was approved by the US Food and Drug Administration (FDA), was used to treat geographic atrophy secondary to age-related macular degeneration.
• In October 2022, Topline results from the NGM621 CATALINA Phase II Trial in patients with geographic atrophy secondary to age-related macular degeneration were released by NGM Bio. The primary goal of a statistically significant rate of change in GA lesion area over 52 weeks for NGM621 versus sham was not met by the trial.
• In July 2022, The US Food and Drug Administration (FDA) approved and given PriorityReview status for the intravitreal pegcetacoplan New Drug Application (NDA), according to a statement from Apellis Pharmaceuticals, Inc. A targeted C3therapy under development called pegcetacoplan is used to treat Geographic Atrophy (GA), which is a complication of age-related macular degeneration (AMD).
• In March 2021, For subjects with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or finished the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600), Apellis Pharmaceuticals started a Phase III, open-label, multicenter extension study.

Geographic Atrophy Overview
Geographic Atrophy (GA), also referred to as atrophic age-related macular degeneration (AMD) or advanced Dry AMD, is an advanced form of age-related macular degeneration that may cause a progressive and irreversible loss of retina (photoreceptors, retinal pigment epithelium, and choriocappillaris), which over time may result in a loss of visual function.

Get a Free Sample PDF Report to know more about Geographic Atrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Geographic Atrophy Drugs Under Different Phases of Clinical Development Include:
• CTx001: Complement Therapeutics
• AAV.sFH: Aevitas Therapeutics
• MCO 020: Nanoscope Therapeutics
• ONL 1204: ONL Therapeutics
• RO7303359: Roche
• NGM621: NGM Biopharmaceuticals
• ANX 007: Annexon
• OpRegen: Genentech
• Pegcetacoplan: Apellis Pharmaceuticals
• Avacincaptad: Pegol Iveric Bio
• IONIS-FB-LRx: Ionis Pharmaceuticals
• Zimura: IVERIC bio

Geographic Atrophy Route of Administration
Geographic Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Geographic Atrophy Molecule Type
Geographic Atrophy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Geographic Atrophy Pipeline Therapeutics Assessment
• Geographic Atrophy Assessment by Product Type
• Geographic Atrophy By Stage and Product Type
• Geographic Atrophy Assessment by Route of Administration
• Geographic Atrophy By Stage and Route of Administration
• Geographic Atrophy Assessment by Molecule Type
• Geographic Atrophy by Stage and Molecule Type

DelveInsight's Geographic Atrophy Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Geographic Atrophy product details are provided in the report. Download the Geographic Atrophy pipeline report to learn more about the emerging Geographic Atrophy therapies at:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Geographic Atrophy Therapeutics Market include:
Key companies developing therapies for Geographic Atrophy are - Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others

Geographic Atrophy Pipeline Analysis:
The Geographic Atrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Geographic Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Geographic Atrophy Treatment.
• Geographic Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Geographic Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Geographic Atrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Geographic Atrophy drugs and therapies-
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Geographic Atrophy Pipeline Market Drivers
• Increase in Patient Burden, development of Novel Treatments, increased Focus on Disease Management and early Diagnosis are some of the important factors that are fueling the Geographic Atrophy Market.

Geographic Atrophy Pipeline Market Barriers
• However, high Cost of Treatment, side-effects associated and other factors are creating obstacles in the Geographic Atrophy Market growth.

Scope of Geographic Atrophy Pipeline Drug Insight
• Coverage: Global
• Key Geographic Atrophy Companies: Complement Therapeutics, Aevitas Therapeutics, Nanoscope Therapeutics, ONL Therapeutics, Roche, NGM Biopharmaceuticals, Annexon, Genentech, Apellis Pharmaceuticals, Pegol Iveric Bio, and others
• Key Geographic Atrophy Therapies: CTx001, AAV.sFH, MCO 020, ONL 1204, RO7303359, NGM621, ANX 007, OpRegen, Pegcetacoplan, Avacincaptad, and others
• Geographic Atrophy Therapeutic Assessment: Geographic Atrophy current marketed and Geographic Atrophy emerging therapies
• Geographic Atrophy Market Dynamics: Geographic Atrophy market drivers and Geographic Atrophy market barriers

Request for Sample PDF Report for Geographic Atrophy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Geographic Atrophy Report Introduction
2. Geographic Atrophy Executive Summary
3. Geographic Atrophy Overview
4. Geographic Atrophy- Analytical Perspective In-depth Commercial Assessment
5. Geographic Atrophy Pipeline Therapeutics
6. Geographic Atrophy Late Stage Products (Phase II/III)
7. Geographic Atrophy Mid Stage Products (Phase II)
8. Geographic Atrophy Early Stage Products (Phase I)
9. Geographic Atrophy Preclinical Stage Products
10. Geographic Atrophy Therapeutics Assessment
11. Geographic Atrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Geographic Atrophy Key Companies
14. Geographic Atrophy Key Products
15. Geographic Atrophy Unmet Needs
16 . Geographic Atrophy Market Drivers and Barriers
17. Geographic Atrophy Future Perspectives and Conclusion
18. Geographic Atrophy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Geographic Atrophy Market https://www.delveinsight.com/report-store/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Geographic Atrophy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Geographic Atrophy Epidemiology https://www.delveinsight.com/report-store/geographic-atrophy-ga-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Geographic Atrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.